Mission:

LEADERSHIP IN THE PREVENTION, TREATMENT, AND CURE OF CANCER THROUGH EXCELLENCE, VISION , AND COST EFFECTIVENESS IN PATIENT CARE, OUTREACH PROGRAMS, RESEARCH, AND EDUCATION.


 www.mskcc.org
 |  1275 YORK AVE NEW YORK NY 10065-6007

MEMORIAL SLOAN-KETTERING CANCER CENTER is headquartered in NEW YORK, NY, and is a 501(c)(3) organization. EIN: 91-2154267.  Donations may or may not be tax-deductible. The IRS' NTEE classification is Hospital, Specialty within the Health - General and Rehabilitative category. The IRS ruling year for tax exemption was 1962.

(Source: IRS Business Master File and Form 990)


...  ...  ...  ...  

Encompass Rating System by Charity Navigator


Charity Navigator’s Encompass Rating System evolves on a quarterly basis as we add new measures and indicators, which we call Beacons. Check back often to see how this organization’s score changes.

Learn about the Encompass Rating System: Announcement | FAQ | Release Notes


Overall Score
BETA

100

out of 100

This charity's score is a passing score.

Do you work for MEMORIAL SLOAN-KETTERING CANCER CENTER? Gain access to your rating toolkit.


Looking for this charity in our old design?

Back to Top

...   Finance & Accountability


Charity Navigator evaluates a nonprofit organization’s financial health including measures of stability, efficiency and sustainability. We also track accountability and transparency policies to ensure the good governance and integrity of the organization.


Finance & Accountability Score
BETA

100

out of 100

This charity's score is a passing score

This Beta V1 of Finance Score provides a baseline measure of an organization’s health including the indicators listed in the report below.

This score represents Form 990 data from latest filing year 2017.



Finance & Accountability Rating Highlights

Higher Effect on Score

Board Composition

103/113 Independent

We look for at least 3 board members, with more than 50% of members identified as independent.

Lower Effect on Score

Liabilities to Assets Ratio

42.60%

Charity Navigator looks for a ratio less than 50%.

No Effect on Score

Total Revenue

$4,499,057,098

Charity Navigator doesn’t evaluate revenue amounts or sources in Beta V1. An organization’s size can affect whether and how we evaluate other indicators.

Back to Top

Finance & Accountability Report

100

of 100 points (BETA)

This beta feature is currently viewable only on desktop or tablet screens. Check back later for updates.

Overview

Overview

The Finance and Accountability Score provides a basic measure for organizational health. At this time, it comprises 100% of a charity's Overall Score.

Program Expense Ratio

96.96%

Higher effect on score

More data  


The Program Expense Ratio is determined by Program Expenses divided by Total Expense (average of most recent three 990s).


For a passing score, Charity Navigator looks for a ratio of 70% or higher. Charities in the 50%-70% range receive zero points for their Program Expense Ratio score. Charities that fall below 50% will receive zero points for both of their financial metric scores, Program Expense Ratio AND Liabilities to Assets Ratio.


Source: IRS Form 990

Board Composition

103/113 Independent

Higher effect on score


Charity Navigator looks for at least 3 board members, with more than 50% of those members identified as independent.


Source: IRS Form 990

Independent Review/Financial Audit

Audited

Higher effect on score


For organizations larger than $1million in total revenue we expect to see that the charity completed an audit.


This indicator is not part of the score for organizations less than $250k in total revenue and is removed from the scoring methodology.


For charities under $1 million but over $250K in total revenue we expect to see that the charity completed an Audit, Review or Compilation.


Source: IRS Form 990

Liabilities to Assets Ratio

42.60%

Lower effect on score


The Liabilities to Assets Ratio is determined by Total Liabilities divided by Total Assets (most recent 990).


Charity Navigator looks for a ratio less than 50%.


Source: IRS Form 990

Website Listed

Listed

Lower effect on score


Charity Navigator looks for a website on the Form 990 as an accountability and transparency measure.


Nonprofits act in the public trust and reporting publicly on activities is an important component


Source: IRS Form 990

Data Sources

IRS Forms 990 are provided courtesy of Foundation Center.

...   Impact & Results


Charity Navigator assesses how well a nonprofit delivers on its mission. To issue an Impact & Results score, we estimate the actual impact a nonprofit has on the lives of those it serves, and determine whether it is making good use of donor resources to achieve that impact.


No Score

We have not issued this nonprofit an Impact & Results score. This does not indicate a positive or negative assessment, only that we have not reached a conclusion for one of the following reasons:

  • The nonprofit is eligible for a score, but we have not yet gotten to scoring it.

  • The nonprofit is eligible for a score, but we have not yet developed the specific algorithms to estimate the impact of the type of service it delivers and so cannot issue a score yet.

  • The nonprofit does not primarily deliver services directly to beneficiaries or it is not reasonable to expect the nonprofit to measure impact for its primary activity. The impact analysis framework that we use is not well suited to these nonprofits.

  • The nonprofit is not heavily reliant on individual donors because beneficiaries fund a majority of its costs or it does not receive any private charitable contributions.

Learn more about how we rate nonprofits.

Do you work at MEMORIAL SLOAN-KETTERING CANCER CENTER? Share your impact data to request a score.


Back to Top

Additional Information

Unscored

This beta feature is currently viewable only on desktop or tablet screens. Check back later for updates.

Largest Programs

Largest Programs



MEMORIAL SLOAN-KETTERING CANCER CENTER reported its three largest programs on its FY 2017 Form 990 as:


$3,230,695,781

Spent in most recent FY

79%

Percent of program expenses


PATIENT CARE: MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERTS HAVE ESTABLISHED STANDARDS OF CARE AND TREATMENT PROTOCOLS FOR EACH TYPE AND STAGE OF CANCER. OUR PHYSICIANS HAVE AN EXTRAORDINARY DEPTH AN ... (More)


$605,096,727

Spent in most recent FY

14%

Percent of program expenses


RESEARCH: MEMORIAL SLOAN-KETTERING CANCER CENTER MAINTAINS ONE OF THE WORLD'S MOST DYNAMIC PROGRAMS OF CANCER RESEARCH. THE EXTRAORDINARY PATIENT CARE WE PROVIDE BENEFITS FROM OUR INNOVATIVE PROGRAMS  ... (More)


$235,502,031

Spent in most recent FY

5%

Percent of program expenses


EDUCATION: EDUCATION IS A VITAL PART OF MEMORIAL SLOAN-KETTERING CANCER CENTER'S MISSION. OUR TRAINING PROGRAMS PREPARE PHYSICIANS AND SCIENTISTS FOR CAREERS IN THE BIOMEDICAL SCIENCES. OUR COLLABORAT ... (More)


GuideStar Seal of Transparency

Gold


GuideStar is Charity Navigator's trusted partner in sharing information on how this organization seeks impact. GuideStar has recognized this organization with a Gold Seal of Transparency for voluntarily and publicly describing their goals, strategies, and accomplishments. Click here for more information.

Note: GuideStar Seals do not effect the nonprofit’s Impact & Results Score.


What is your organization aiming to accomplish?

Memorial Sloan Kettering's vision is nothing less than to revolutionize the treatment of cancer. Our goal over the next decade is to integrate molecular and clinical information to develop therapies that home in on the abnormalities driving each patient's disease. At MSK, this new era in precision cancer medicine is already a reality for many of our patients


What are your strategies for making this happen?

Capitalizing on our exceptionally powerful combination of clinical and scientific resources, we are delivering on the promise of personalized cancer therapy and are setting the stage for transformational change, both in the immediate future and for years to come. At MSK, we’ve created new ways to facilitate more discoveries, even more rapidly and have put in place creative new approaches to sharing. We’re reaching within our own walls and beyond them to move what we know about cancer research, treatment, and care delivery into an ever-expanding universe of patients, fellow clinicians, and scientists. MSK investigators working in a variety of areas collaborate with one another as well as with scientists and clinicians from other academic and research institutions around the nation. Teaming with other organizations allows us to make the most of our expertise in cancer research and related topics while gaining valuable insight from researchers who are focused on the same overarching goals — exploring new ways to cure, control, and prevent disease. Among our ongoing extramural collaborations are the New York State Stem Cell Science Consortia, the Starr Cancer Consortium, the Tri-Institutional Stem Cell Initiative, the Tri-Institutional Therapeutics Discovery Institute, and the Physical Sciences-Oncology Center. In addition, in 2012, the leadership of MSK endorsed a $2.2 billion investment in a clinical expansion that is setting the stage for a changing care paradigm into the next decade and beyond. There are several tangible components of our clinical strategic plan, among them an outpatient cancer building, the David H. Koch Center for Cancer Care. This new center scheduled to open in 2019 will enable us to provide cancer care in a facility designed to adapt to the ways in which cancer will be diagnosed and treated in the coming decades. We will provide leading-edge treatment for patients with hematologic cancers such as leukemia and lymphoma, head and neck cancers, and thoracic cancers. The facility will also support our efforts to offer bone marrow transplants in the outpatient setting and a focused environment for early-stage clinical trials. Other elements of the capital program include the Josie Robertson Surgical Center on York Avenue (scheduled to open in 2016), which will feature 12 operating rooms equipped to provide technologically sophisticated surgical care on an outpatient basis. MSK is also planning a new facility that will house a clinical laboratory and research building and will accommodate all specialized testing, along with a cell bank, a cell therapy facility, and tumor procurement services. New regional facilities in West Harrison, New York, and Monmouth County, New Jersey (slated to open in 2016), have joined our growing network of suburban campuses in Westchester County, on Long Island, and in New Jersey, all of which offer a convenient point of access for patients seeking MSK's quality of care.


What are your organization's capabilities for doing this?

With nearly 1,000 attending physicians and 140 senior laboratory investigators, we maintain one of the world’s most dynamic programs of cancer research. More than 120 research laboratories are focused on better understanding every form of the disease and 35 state-of-the-art core facilities provide our research community with the latest research technology and a range of expert services. Research at the Sloan Kettering Institute (SKI), MSK’S basic research arm, is dedicated to understanding the biology of cancer through nine major research programs. Investigators at SKI collaborate with Memorial Hospital physician-scientists — a partnership that helps speed important research findings from the laboratory to the patient. Memorial Hospital’s extensive research program includes areas that focus on basic laboratory research, translational research that bridges discoveries made in the laboratory and those made in the clinic, and mathematical and computational research directed at analyzing and interpreting biomedical data. MSK also conducts one of the largest clinical research programs in the world. Through these studies, physicians and scientists on our disease-focused research teams translate basic science findings into new treatment advances. In addition, MSK actively initiates and participates in clinical trials to identify more-effective cancer therapies. The world-class patient care we provide benefits from all these innovative programs in basic, clinical, and translational research. In fact, between 1980 and 2012, the U.S. Food and Drug Administration approved nine drugs developed in our labs for marketing — a success rate unmatched by any other cancer center. In addition, we have an array of collaborative centers within the institution that draw on the breadth of our scientific expertise, bringing together laboratory investigators and clinicians from a range of disciplines to focus on strategically important areas of cancer research. These centers include the Center for Cell Engineering, the Center for Epigenetics Research, the Center for Experimental Therapeutics, the Center for Metastasis Research, the Center for Molecular Imaging and Nanotechnology, the Center for Stem Cell Biology, the Center of Comparative Medicine and Pathology, the David M. Rubenstein Center for Pancreatic Cancer Research, the Fiona and Stanley Druckenmiller Center for Lung Cancer Research, the Geoffrey Beene Cancer Research Center, the Lucille Castori Center for Microbes, Inflammation and Cancer, the Ludwig Center for Cancer Immunotherapy, and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology.


How will your organization know if you are making progress?

Our scientists and clinicians work relentlessly to answer critical questions about cancer and make seminal contributions to the development of new and innovative therapies that are improving the lives of the patients we see today and those we will care for tomorrow. Pinpointing the genetic changes that cause cancer has been a special focus of researchers here at MSK and elsewhere for more than a decade. MSK has extensive experience in this area and has developed a pioneering test — called MSK-IMPACT™ — that can reliably and accurately screen for mutations in more than 400 genes. Today, when a patient leaves MSK after a biopsy, their tumor sample takes a different path. It travels to an MSK laboratory where it is tested for these genetic mutations. The results help our doctors determine which drug or drug combination may work best for each patient, based on their genetic profile rather than where the tumor originated. Genetic screening will become even more routine and our researchers will gain access to even more data; as they do, they will work to refine old targets and find new ones, in order to get therapies to more patients, even faster. We have already made tremendous strides in cancer research and treatment at MSK. Many of the approaches developed or pioneered here have become the standard of care worldwide. We will know we are making even more progress as our investigators reveal more about the biological underpinnings of cancer and as the numbers of cancer survivors continue to rise, both nationally and internationally


What have and haven't you accomplished so far?

Our overarching goal is to improve patient outcomes and to extend our expertise to as many patients as possible. Our vision is to develop and bring treatments to patients that were not available before — indeed, that did not exist before. MSK investigators and clinicians have made cancer treatment not only more effective but significantly more tolerable for patients receiving these treatments. Targeted therapies, many of which were developed by MSK researchers, generally come with fewer side effects than conventional systemic chemotherapies. Radiation techniques — many of which were also pioneered at MSK — allow radiation to be delivered more precisely and in higher doses than ever before, killing cancer cells while sparing nearby healthy tissue. Cancer surgery is growing less invasive and increasingly operations can now be done by our expert surgeons on an outpatient basis, allowing patients to return home the same day. However, challenges remain. There is still much to learn about cancer: How it develops, how it grows and spreads, and how to prevent the disease in the first place. And Memorial Sloan Kettering is in a unique position to do the bold, innovative, and multidisciplinary research required and to rapidly apply our findings to the clinical setting. We are excited about the future and are enormously optimistic that recent advances — and advances to come — will expand the benefits of personalized therapy to all patients with cancer.



GlobalGiving


GlobalGiving Badge not earned

GlobalGiving is the largest global crowdfunding community connecting nonprofits, donors, and companies in nearly every country. For donors, GlobalGiving provides an additional layer of vetting and due diligence for each of its nonprofit partners every two years, which may include site visit verification. Learn more about GlobalGiving.

Note: GlobalGiving Badges do not effect the nonprofit’s Impact & Results score.


...   Leadership & Adaptability


Charity Navigator will provide an assessment of the organization’s leadership capacity, strategic planning, and the ability to readily innovate or respond to changes in constituent demand/need or other relevant social and economic conditions to achieve the organization’s mission.


Leadership & Adaptability Score (BETA)

Coming Soon

Encompass Rating Beta V2 does not provide an evaluation of the organization's leadership and adaptability.


Back to Top

...   Culture & Community


Charity Navigator will provide an assessment of the organization’s people operations, connectedness and engagement with the constituents and communities served, and Diversity, Equity and Inclusion measures.


Culture & Community Score (BETA)

Coming Soon

Encompass Rating Beta V2 does not provide an evaluation of the organization's culture and community.


Back to Top